Spero Therapeutics to Present at Upcoming September Investor Conferences
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focusing on rare diseases and multi-drug resistant bacterial infections, has announced its participation in two upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (September 9-11, 2024)
- Presentation: September 10, 2024, 4:00 - 4:30 PM ET
2. Cantor's Global Healthcare Conference in New York, NY (September 17-19, 2024)
- Fireside Chat: September 17, 2024, 1:20 - 1:50 PM ET
Sath Shukla, President and CEO of Spero Therapeutics, will present at both events and be available for one-on-one meetings. Webcasts of both presentations will be accessible through Spero's website, with replays available after the events.
Spero Therapeutics (Nasdaq: SPRO), un'azienda biofarmaceutica in fase clinica focalizzata su malattie rare e infezioni batteriche multiresistenti, ha annunciato la sua partecipazione a due conferenze per investitori che si terranno nel settembre 2024:
1. 26esima Conferenza Annuale di Investimento Globale H.C. Wainwright a New York, NY (9-11 settembre 2024)
- Presentazione: 10 settembre 2024, 16:00 - 16:30 ET
2. Conferenza Globale sulla Salute di Cantor a New York, NY (17-19 settembre 2024)
- Conversazione informale: 17 settembre 2024, 13:20 - 13:50 ET
Sath Shukla, Presidente e CEO di Spero Therapeutics, interverrà a entrambi gli eventi e sarà disponibile per incontri individuali. Le registrazioni di entrambe le presentazioni saranno accessibili tramite il sito web di Spero, con repliche disponibili dopo gli eventi.
Spero Therapeutics (Nasdaq: SPRO), una compañía biofarmacéutica en etapa clínica centrada en enfermedades raras e infecciones bacterianas multirresistentes, ha anunciado su participación en dos conferencias de inversores que se llevarán a cabo en septiembre de 2024:
1. 26ª Conferencia Anual de Inversión Global H.C. Wainwright en Nueva York, NY (9-11 de septiembre de 2024)
- Presentación: 10 de septiembre de 2024, 16:00 - 16:30 ET
2. Conferencia Global de Salud de Cantor en Nueva York, NY (17-19 de septiembre de 2024)
- Charla informal: 17 de septiembre de 2024, 13:20 - 13:50 ET
Sath Shukla, Presidente y CEO de Spero Therapeutics, presentará en ambos eventos y estará disponible para reuniones uno a uno. Las grabaciones de ambas presentaciones se podrán acceder a través del sitio web de Spero, con repeticiones disponibles después de los eventos.
스페로 테라퓨틱스 (Nasdaq: SPRO), 희귀 질환 및 다약물 내성 세균 감염에 집중하는 임상 단계의 생명공학 회사가 2024년 9월에 있을 두 개의 투자자 회의에 참여한다고 발표했습니다:
1. H.C. 웨인라이트 제26회 연례 글로벌 투자 회의 뉴욕, NY (2024년 9월 9-11일)
- 발표: 2024년 9월 10일, 오후 4:00 - 4:30 ET
2. 칸토 글로벌 헬스케어 회의 뉴욕, NY (2024년 9월 17-19일)
- 라이브 대화: 2024년 9월 17일, 오후 1:20 - 1:50 ET
스태스 슈클라 스페로 테라퓨틱스의 사장 겸 CEO가 두 행사에서 발표하며, 일대일 미팅도 진행할 예정입니다. 두 발표의 웹캐스트는 스페로 웹사이트를 통해 접근 가능하며, 행사 후 다시 볼 수 있습니다.
Spero Therapeutics (Nasdaq: SPRO), une entreprise biopharmaceutique en phase clinique axée sur les maladies rares et les infections bactériennes multirésistantes, a annoncé sa participation à deux conférences d'investisseurs à venir en septembre 2024 :
1. 26e Conférence Annuelle d'Investissement Mondial H.C. Wainwright à New York, NY (9-11 septembre 2024)
- Présentation : 10 septembre 2024, 16h00 - 16h30 ET
2. Conférence Mondiale sur la Santé de Cantor à New York, NY (17-19 septembre 2024)
- Discussion informelle : 17 septembre 2024, 13h20 - 13h50 ET
Sath Shukla, Président et CEO de Spero Therapeutics, interviendra lors de ces deux événements et sera disponible pour des réunions individuelles. Les webdiffusions des deux présentations seront accessibles via le site Web de Spero, avec des rediffusions disponibles après les événements.
Spero Therapeutics (Nasdaq: SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten und multiresistente bakterielle Infektionen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben:
1. 26. Jährliche Globale Investorenkonferenz von H.C. Wainwright in New York, NY (9.-11. September 2024)
- Präsentation: 10. September 2024, 16:00 - 16:30 Uhr ET
2. Cantor's Globale Gesundheitskonferenz in New York, NY (17.-19. September 2024)
- Fireside Chat: 17. September 2024, 13:20 - 13:50 Uhr ET
Sath Shukla, Präsident und CEO von Spero Therapeutics, wird an beiden Veranstaltungen präsentieren und für persönliche Gespräche zur Verfügung stehen. Die Webcasts beider Präsentationen sind über die Website von Spero zugänglich und die Aufzeichnungen sind nach den Veranstaltungen verfügbar.
- None.
- None.
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference to be held in New York, NY, September 9th – 11th, 2024. He will also participate in a fireside chat and be available for one-on-one meetings at Cantor’s Global Healthcare Conference in New York, NY, September 17th – 19th, 2024. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference | |
Presentation Date: | September 10, 2024 |
Time: | 4:00 - 4:30 PM ET |
Webcast link: | Company Presentation |
Cantor’s Global Healthcare Conference | |
Analyst Fireside Chat: | September 17, 2024 |
Time: | 1:20 - 1:50 PM ET |
Webcast link: | Fireside Chat |
The webcasts may also be accessed through Spero’s website on the “Events and Presentations” page (https://www.sperotherapeutics.com/investor-relations). A replay will be available on the website following the conclusion of the event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When is Spero Therapeutics (SPRO) presenting at the H.C. Wainwright Global Investment Conference in September 2024?
What is the date and time of Spero Therapeutics' (SPRO) fireside chat at Cantor's Global Healthcare Conference in 2024?
Who will represent Spero Therapeutics (SPRO) at the September 2024 investor conferences?